AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Company profile
Ticker
AZN, AZNCF
Exchange
Website
CEO
Pascal Soriot
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ZENECA GROUP PLC
SEC CIK
AZN stock data
Latest filings (excl ownership)
6-K
Odac Reviewed Imfinzi In Resectable Lung Cancer
26 Jul 24
6-K
Current report (foreign)
25 Jul 24
6-K
Acquisition of Amolyt Pharma Completed
15 Jul 24
6-K
Total Voting Rights
1 Jul 24
6-K
Lynparza & Imfinzi Positive CHMP In Endometrial
1 Jul 24
6-K
Update on Imfinzi Adjuvant BR.31 Trial
25 Jun 24
6-K
Imfinzi Improved Efs and Os In Bladder Cancer
25 Jun 24
6-K
Update on CAPITELLO-290 Phase III Trial
18 Jun 24
6-K
Imfinzi Approved In the Us for Endometrial Cancer
17 Jun 24
6-K
Director/pdmr Shareholding
12 Jun 24
Latest ownership filings
11-K
Annual report of employee stock purchases
26 Jun 24
SC 13G/A
ADC Therapeutics SA
12 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13D/A
Cellectis S.A.
16 Nov 23
144
Notice of proposed sale of securities
13 Nov 23
SC 13D
Cellectis S.A.
9 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
Aridis Pharmaceuticals, Inc.
10 Feb 23
SC 13G/A
PIERIS PHARMACEUTICALS, INC.
10 Feb 23
SC 13G/A
BlackRock Inc.
24 Jan 23
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
News
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
26 Jul 24
The FDA's Oncologic Drugs Advisory Committee Acknowledged AstraZeneca's Imfinzi (Durvalumab) Met Primary Endpoint Of Event-free Survival For Resectable Non-small Cell Lung Cancer Based On AEGEAN Phase 3 Trial Results With Overall Tolerable Safety Profile
26 Jul 24
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
25 Jul 24
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
25 Jul 24
CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
25 Jul 24
Press releases
AstraZeneca's H1 and Q2 2024 Financial Results
25 Jul 24
Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca
23 Jul 24
Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis
23 Jul 24
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
20 Jun 24
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
19 Jun 24